Hostname: page-component-77f85d65b8-5ngxj Total loading time: 0 Render date: 2026-03-30T08:12:26.244Z Has data issue: false hasContentIssue false

Oral administration of veratric acid, a constituent of vegetables and fruits, prevents cardiovascular remodelling in hypertensive rats: a functional evaluation

Published online by Cambridge University Press:  08 September 2015

Murugesan Saravanakumar
Affiliation:
Department of Physiology, College of Medicine, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA Cardiovascular Biology Lab, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India
Boobalan Raja*
Affiliation:
Cardiovascular Biology Lab, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India
Jeganathan Manivannan
Affiliation:
Cardiovascular Biology Lab, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India Vascular Biology Lab, AU-KBC Research Centre, Anna University, Chennai, Tamil Nadu 600044, India
Thangarasu Silambarasan
Affiliation:
Cardiovascular Biology Lab, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India
Pichavaram Prahalathan
Affiliation:
Cardiovascular Biology Lab, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India
Subramanian Kumar
Affiliation:
Cardiovascular Biology Lab, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India
Santosh Kumar Mishra
Affiliation:
Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243122, India
*
* Corresponding author: Dr B. Raja, email drrajaau@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

In our previous studies, veratric acid (VA) shows beneficial effect on hypertension and its associated dyslipidaemia. In continuation, this study was designed to investigate the effect of VA, one of the major benzoic acid derivatives from vegetables and fruits, on cardiovascular remodelling in hypertensive rats, primarily assessed by functional studies using Langendorff isolated heart system and organ bath system. Hypertension was induced in male albino Wistar rats by oral administration of N ω -nitro-l-arginine methyl ester hydrochloride (l-NAME) (40 mg/kg body weight (b.w.)) in drinking water for 4 weeks. VA was orally administered at a dose of 40 mg/kg b.w. l-NAME-treated rats showed impaired cardiac ventricular and vascular function, evaluated by Langendorff isolated heart system and organ bath studies, respectively; a significant increase in the lipid peroxidation products such as thiobarbituric acid-reactive substances and lipid hydroperoxides in aorta; and a significant decrease in the activities of superoxide dismutase, catalase, glutathione peroxidase and levels of GSH, vitamin C and vitamin E in aorta. Fibrotic remodelling of the aorta and heart were assessed by Masson’s Trichrome staining and Van Gieson’s staining, respectively. In addition, l-NAME rats showed increased heart fibronectin expression assessed by immunohistochemical analysis. VA supplementation throughout the experimental period significantly normalised cardiovascular function, oxidative stress, antioxidant status and fibrotic remodelling of tissues. These results of the present study conclude that VA acts as a protective agent against hypertension-associated cardiovascular remodelling.

Information

Type
Full Papers
Copyright
Copyright © The Authors 2015 
Figure 0

Fig. 1 Structure of veratric acid; the chemical structure was obtained from the PubChem database (pubchem.ncbi.nlm.nih.gov).

Figure 1

Table 1 Effect of veratric acid (VA) on lipid peroxidation and antioxidants in the aorta of experimental hypertensive rats (Mean values and standard deviations; six animals)

Figure 2

Fig. 2 Veratric acid improved cardiac ventricular function in experimental hypertensive rats. Values are means (six animals), and standard deviations represented by vertical bars. * Mean values were significantly different compared with control (P<0·05; Duncan’s multiple-range test). † Mean values were significantly different compared with Nω-nitro-l-arginine methyl ester hydrochloride (l-NAME) (P<0·05; Duncan’s multiple-range test). , Control; , control+veratric acid; , l-NAME; , l-NAME+veratric acid.

Figure 3

Fig. 3 Veratric acid recovered vascular function in experimental hypertensive rats. Values are means (six animals), and standard deviations. * Mean values were significantly different compared with control (P<0·05; Bonferroni’s post hoc test). † Mean values were significantly different compared with Nω-nitro-l-arginine methyl ester hydrochloride (l-NAME) (P<0·05; Bonferroni’s post hoc test). ACh, acetylcholine; ■, control; , control+veratric acid; , l-NAME; , l-NAME+veratric acid.

Figure 4

Table 2 Effect of veratric acid (VA) on acetylcholine-induced relaxations in endothelium-intact aorta of experimental hypertensive rats (Mean values and standard deviations; six animals)

Figure 5

Fig. 4 Photomicrographs of Masson’s Trichrome-stained sections of thoracic aorta from control and Nω-nitro-l-arginine methyl ester hydrochloride (l-NAME)-induced hypertensive rats (40×). (a) Control rats showing normal pathological staining. (b) Control+veratric acid (VA) (40 mg/kg)-treated rats showing negative staining without any pathological alterations. (c) l-NAME-induced hypertensive rats showing increased endothelial cells and interstitial collagen accumulation (stained blue). (d) l-NAME+VA (40 mg/kg) revealed reduced collagen accumulation (stained blue) as compared with the hypertensive rats.

Figure 6

Fig. 5 Photomicrographs of Van Gieson’s stained sections of heart from control and Nω-nitro-l-arginine methyl ester hydrochloride (l-NAME)-induced hypertensive rats (40×). (a) Control rats showing normal pathological staining. (b) Control+veratric acid (VA) (40 mg/kg)-treated rat showing negative staining without any pathological alterations. (c) l-NAME-induced hypertensive rats showing pathological alteration with positive staining (fibrosis and collagen deposition). (d) l-NAME+VA (40 mg/kg) rats showing reduced positive staining.

Figure 7

Fig. 6 Representative photomicrographs of immunohistochemistry for fibronectin in heart of control and Nω-nitro-l-arginine methyl ester hydrochloride (l-NAME)-induced hypertensive rats (40×). (a) Control rats showing normal architecture without any pathological alterations (0=negative, <1 % of area staining). (b) Control+veratric acid (VA) (40 mg/kg)-treated rats showing near normal architecture (0=negative, <1 % of area staining). (c) l-NAME hypertensive rats showing increased fibronectin-positive staining (2+=moderate staining, between 20 and 50 % of area was stained). (d) l-NAME+VA (40 mg/kg)-treated rat showing diminished fibronectin expression (1+=weak staining, between 1 and 20 % of area was stained).

Figure 8

Fig. 7 Preventive role of veratric acid on cardiovascular remodelling. iNOS, inducible nitric oxide synthase.